CSPC Mingfule Pharmaceutical

CSPC Mingfule Pharmaceutical is a specialized biopharmaceutical subsidiary of CSPC Pharmaceutical Group, focused on the development of advanced thrombolytic medications. The company's core product is Mingfule (rhTNK-tPA), a third-generation recombinant human tissue-type plasminogen activator designed for rapid treatment of thrombotic conditions. Mingfule is currently marketed in China for acute myocardial infarction and was recently approved for the treatment of acute ischemic stroke within a 4.5-hour window. Based in Guangzhou, the company maintains high-standard manufacturing capabilities for biologics and plays a critical role in CSPC's cardiovascular and cerebrovascular portfolio. The acquisition of Mingfule has significantly strengthened CSPC's position in the emergency medicine market for stroke and heart attack treatments.